Search for content, post, videos

Trading of Alligator on Nasdaq has begun


Alligator Bioscience has started trading of its shares on the main market of Nasdaq Stockholm.

Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies and is primarily active in the early phases of drug development, from the idea stage to clinical phase II trials. Alligator Bioscience was founded in 2001 and is headquartered at Medicon Village in Lund, Sweden. Alligator’s product portolio primarily consist of the product candidates ADC-1013, ATOR-1015 and ATOR-1016. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization.

“We are pleased by the confidence shown in us by current and new institutional and private investors. It is an acknowledgment to both our history and potential going forward. The IPO is an important step in realizing our strategy of becoming the leading research-based company within tumor-directed immunotherapy, and we look forward to continue our journey as a listed company,” said Per Norlén, CEO Alligator.


Carnegie is Global Co-ordinator and Joint Bookrunner, DNB Markets is Joint Bookrunner and Redeye is Co-Lead Manager (together the ”Managers”). Setterwalls Advokatbyrå AB is legal advisor to the Company and Baker & McKenzie Advokatbyrå KB is legal advisor to the Managers.


As previously announced, the price per share in the Offering was SEK 32.50, corresponding to a value of the total number of shares in the Company upon completion of the Offering of SEK 2,275 million. The Offering consisted of 12,923,077 shares, corresponding to approximately 18.5 percent of the total number of shares in the Company upon completion of the Offering, of which 10,769,231 were new shares offered by the Company and 2,153,846 are existing shares offered by Sunstone Life Science Ventures Fund II K/S and Duba AB.

Photo: Jenny Leyman